菜单

Late-Stage Development

Bring High-Quality Biologics to Market—Faster

WuXi Biologics’ late-stage development services meet the highest global standards while delivering speed and cost efficiency. Starting with commercial process development (CPD), we optimize and scale your process for commercialization, then progress through characterization, qualification, and validation. Our fully integrated approach readies your biologic for BLA submission in as little as 18 months.

Accelerate BLA Today

Connect with Us

Commercial Process Development

CPD transforms clinical-stage processes into robust, scalable manufacturing workflows optimized for commercial readiness, regulatory alignment, and cost efficiency. Services include process optimization, scale-up, technology transfer, and raw material qualification.

Bioprocessing Platforms and Digital Technology

Our bioprocessing platforms—WuXiUI™ for intensified perfusion culture, WuXiUP™ upstream and downstream operations—power CPD. They support scalable, manufacturing-ready processes while reducing cost of goods sold (COGS). Support for traditional fed-batch, intensified fed-batch, traditional perfusion, and other major process modes maximizes flexibility.

The PatroLab™ digital platform further strengthens process insight and scalability with real-time monitoring, predictive modeling, and automated control to deepen product and process understanding. Accurate predictions across scales from 3 to 16,000 L help remove uncertainty from scale-up.

Proven Performance for Commercial Manufacturing

Exceptional Upstream Productivity

  • Achieve up to 9× higher drug substance productivity versus traditional fed-batch.
  • Reach fed-batch titers of 35 g/L in a 14-day culture.
  • Reduce COGS by at least 40% with MagniCHO™ cell culture media.

Cost-Efficient Manufacturing by Design

  • Improve downstream yields by 10 to 15%.
  • Lower raw material usage by 20 to 60%.
  • Simplify operations, optimize cadence, and maximize facility use.
  • Reduce COGS by 60 to 80%.

Reliable Speed and Scale

  • Complete CPD and optimization in 3 to 5 months.
  • Conduct drug substance process characterization in 4 to 8 months.
  • Predict > 40 in-process targets and product quality attributes with > 1,000× the data density of standard monitoring.
  • Support over 80 late-stage programs annually with global capacity.

Sustainable by Strategy

Upstream and Downstream Technology Gains

Our integrated upstream and downstream innovations enhance yield, consistency, and facility fit—accelerating your path to commercialization.

Data-Driven Quality Monitoring and Method Development

We offer a full suite of analytical services, developed and validated in-house, to support product identity, purity, safety, and comparability.

Physicochemical Assays

  • HPLC-based: SEC, CEX, RP, HIC, titer, polysorbates, sialic acid, peptide mapping, glycan profiling
  • CE-based: Reduced and non-reduced CE-SDS, icIEF
  • Mass spectrometry: Intact, reduced, and deglycosylated mass, peptide mapping, disulfide bonds, sequence variants

Biological Assays

  • ELISA, enzyme activity, binding kinetics (BLI), neutralization, anti-proliferation, ADCC, ADCP, CDC, and more

Compendial and Biochemistry Assays

  • Appearance, pH, osmolality, extractable volume, visible and subvisible particles
  • Residual host cell protein (HCP), DNA, Protein A; Western blot; SDS-PAGE

BLA-Enabling Studies

Our BLA-enabling studies provide the critical product and process understanding that successful regulatory submission requires. The studies include resin and membrane reuse, viral clearance, impurity control, and comparability assessments.

Conducted at lab scale for cost-efficiency and speed, our resin and membrane lifetime studies establish safe reuse limits and generate used resins for BLA-enabling viral clearance. A structured 5-step workflow ensures consistency, quality, and regulatory readiness.

Highlights:

  • Custom scale-down model design
  • Cycle-stop criteria by unit operation
  • Full in-process analytics and logistics
  • Data insights across more than 50 resin and membrane types

WuXi Biologics delivers robust viral clearance studies to meet global regulatory expectations. Our BLA packages include viral inactivation, chromatography with mass balance, new and aged resin performance, and carryover assessments.

WuXi Biologics’ in-depth product characterization defines a drug product’s structure, function, and variability. This characterization supports safety, efficacy, and regulatory acceptance, enabling watertight process characterization.

Our comparability studies confirm product consistency before and after manufacturing changes through a structured, stepwise workflow that maintains quality, safety, and efficacy.

Highlights:

  • Completed over 40 BLA-enabling programs
  • Profiled variants in less than 2 months
  • Completed forced degradation in less than 3 months
  • Fractionalized size and charge variants at milligram scale
  • Leveraged high-resolution structural tools and biofunctional analysis

Our comparability studies combine in-depth product characterization with a structured, pre- to post-change workflow, ensuring consistent quality safety and efficacy after manufacturing changes.

WuXi Biologics conducts process-related impurity assessments aligned with ICH Q6B to ensure product quality and patient safety. Our highly specific, highly sensitive analytical methods establish impurity limits, support regulatory compliance, and safeguard product performance.

Highlights:

  • Address impurities from both cell culture and downstream purification
  • Apply advanced analytical methods for precise impurity qualification and quantification
  • Support acceptance criteria to meet global regulatory standards

Leveraging onsite laboratories, an exclusive HCP database, and liquid chromatography-mass spectrometry, WuXi Biologics delivers HCP detection services. These integrated capabilities support regulatory filings and product safety, and include:

  • ELISA kit development
  • Coverage assessment
  • Mass spectrometry profiling
  • Method development
  • Risk assessment

Related Offerings

[Webinar] Mastering BLA readiness: Advanced Process Characterization for Robust and Accelerated Process Validation and Biologics Commercialization

Watch Now

[Webinar] The Innovation Edge: Transforming Technologies for Commercial Manufacturing of Biologics

Watch Now

[Service Overview] Late Stage CMC Development Service Overview

Download Now

Connect with our Experts

Let’s discuss your project needs.
Contact Us